Hollander E, DeCaria C M, Schneier F R, Schneier H A, Liebowitz M R, Klein D F
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032.
J Clin Psychiatry. 1990 Mar;51(3):119-23.
Seven patients who met DSM-III-R criteria for obsessive compulsive disorder and had only a partial response to the serotonin reuptake blockers fluoxetine, fluvoxamine, or clomipramine or were unable to tolerate therapeutic doses of these agents due to side effects underwent open treatment with fenfluramine augmentation. Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent. In doses of 20 to 60 mg/day, fenfluramine augmentation was well tolerated and resulted in a further decrease in obsessions and compulsions in six of these patients. Larger controlled studies are needed to confirm this finding.
七名符合《精神疾病诊断与统计手册第三版修订本》（DSM-III-R）中强迫症标准的患者，他们对5-羟色胺再摄取阻滞剂氟西汀、氟伏沙明或氯米帕明仅有部分反应，或者因副作用无法耐受这些药物的治疗剂量，接受了用芬氟拉明增强治疗的开放性治疗。芬氟拉明是一种5-羟色胺释放剂和再摄取阻滞剂，作为一种食欲抑制剂上市。以每天20至60毫克的剂量使用，芬氟拉明增强治疗耐受性良好，其中六名患者的强迫观念和强迫行为进一步减少。需要进行更大规模的对照研究来证实这一发现。
